Hi Kevin, I saw your message yesterday and I emailed the contact I have at Dizal. This was the exact response I received this morning (see below). Frustrating, I know! Dear Stefanie, We appreciate your follow-up. Right now, we are actively working to establish the necessary infrastructure and...
Hi all - was curious if anyone's heard any recent updates regarding sunvozertinib access or have been successful in getting it at their institution? Best, -kevin
Hello Thoracic Team, Do you hold RET inhibitors (given their off-target VEGFR1 and VEGFR3 inhibition) for patients requiring dental surgery with manipulation around the jaw bone or only if on concurrent antiresorptive therapy with bisphosphonates or denosumab? I am seeing a low risk of ONJ in...
Our specialty pharmacy had initially been in contact with someone who said it would be available Q4 of this year but have since found out it likely won't be until 2026 sometime
Yes, on 8/19/25 we were given the following information from the individual whose contact information I am copying below. I apologize that it is likely not the response you wanted to hear (it certainly is not what we were hoping to hear): At the moment, the drug will not be available for another...
Does anyone have a contact at Dizal Pharmaceuticals or been successful in contacting them about sunvozertinib?
Hi Kate, Sounds like a tricky situation. Agree with Lauren that these exon18 mutations may respond better to second-generation EGFR TKIs. There's some in-vitro data suggesting that the E709 T710delinsD may actually be more afatinib sensitive than the other more exon18 mutations seen such as...
Kate, We recently had a patient with both EGFR L858R and EGFR Exon 18 E709. She progressed on Osimertinib monotherapy after just under 2 years. We also debated next steps for her and ended up going with afatinib monotherapy based on https://pubmed.ncbi.nlm.nih.gov/38578683/ and other articles...
Membership
JoinBenefitsRenew Your Membership
Privacy & Terms
About UsCode of Conduct